MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area.
Acute intracerebral injections of MPP+ in the mouse can cause behavioural and biochemical correlates of nigrostriatal dopamine dysfunction, but these are most marked and consistent when injections are directed at the dopamine nerve terminal area (CP) rather than the cell body area (SN). This adds further support to the hypotheses that a locus of neurotoxic action of MPTP/MPP+ may reside in the dopamine cell terminal regions.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects*; D004298:Dopamine / Q000032:analysis / Q000502:physiology*; D005260:Female; D006719:Homovanillic Acid / Q000032:analysis; D008032:Limbic System / Q000187:drug effects*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D009411:Nerve Endings / Q000187:drug effects; D013378:Substantia Nigra / Q000187:drug effects*
D015102:3,4-Dihydroxyphenylacetic Acid; D004298:Dopamine; D006719:Homovanillic Acid